Stocktoria
ICON PLC ICLR
ICON PLC (ICLR) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $8.3B at a 2.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-31 | Citigroup | Neutral (main) |
| 2026-07-31 | Truist Securities | Buy (reit) |
| 2026-06-30 | Truist Securities | Buy (up) |
| 2026-06-26 | Mizuho | Outperform (main) |
| 2026-06-25 | Citigroup | Neutral (main) |
| 2026-06-25 | BMO Capital | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.019 |
| Retained earnings / assets | 0.13 |
| EBIT / assets | 0.027 |
| Equity / liabilities | 1.299 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ICLR | ICON PLC | 6/9 | 2.1 | 56.7 | +0.8% |
| INCY | INCYTE CORP | 6/9 | 7.9 | 17.7 | +21.2% |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | 4/9 | 1.81 | — | -0.9% |
| MEDP | Medpace Holdings, Inc. | 6/9 | 0.2 | 33.4 | +20% |
| IQV | IQVIA HOLDINGS INC. | 5/9 | 1.14 | 23.5 | +5.9% |
| NRC | NRC HEALTH | 3/9 | 0.03 | — | -4% |
| OABI | OmniAb, Inc. | 1/9 | 6 | — | -29.3% |
About ICON PLC
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
FAQ
Is ICLR financially healthy?
ICON PLC's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does ICLR pay a dividend?
No, ICON PLC does not currently pay a dividend.
How profitable is ICLR?
In FY2025, ICON PLC had a net margin of 2.8% and a return on equity of 2.5%.
Is ICLR overvalued or undervalued?
ICON PLC trades at about 57.6× trailing earnings — above its 10-year norm (10-year range 18.1×–118.1×, median 33.1×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for ICLR?
The average Wall-Street price target for ICON PLC is $185.56, about 11.0% above the recent price, from 16 analysts (consensus: buy).
Is ICLR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ICON PLC: a Piotroski F-score of 6/9, an Altman Z″ in the grey zone, a P/E of about 56.7×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.